Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Empliciti (elotuzumab), in combination with Revlimid (lenalidomide) and dexamethasone, did not significantly extend the time people with multiple myeloma lived without disease progression, compared with Revlimid and dexamethasone alone, ... Read more
Amgen announced it will present new data on its cancer portfolio at the 21st Congress of the European Hematology (EHA) Association taking place next month in Copenhagen. The data will include recent evaluations of ... Read more
Genmab has announced positive results from its Phase 3 POLLUX study investigating the efficacy of daratumumab, in combination with lenalidomide and dexamethasone, to treat patients with relapsed or refractory multiple myeloma, compared ... Read more
Leisure-time physical activity is associated with a lower risk for many types of cancer, including a 17 percent lower risk for myeloma. These key findings were independent of body size or smoking ... Read more
Researchers in the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a new animal model of multiple myeloma, which will hopefully allow ... Read more
Researchers at Buffalo, New York-based Roswell Park Cancer Institute revealed that knocking down individual RabGTPases (Rab) proteins in myeloma cells was sufficient to disrupt the trafficking of monoclonal protein, but did ... Read more
A research team led by William Matsui, MD, and Carol Ann Huff, MD, with the Johns Hopkins Kimmel Cancer Center, has found that MedImmune’s novel MEDI-551 antibody treatment effectively decreased the number of ... Read more